Neurol. praxi. 2018;19(3):213-217 | DOI: 10.36290/neu.2018.147

Depression in neurologic disorders, incidence and its treatment

MUDr. Sylva Racková
Psychiatrická ambulance, Plzeň

Depression belons among the most frequent comorbities in neurologic disorders. Its prevalence is higher and depression influencesthe course of neurologic disorders. There is very important the right choice of antidepressant treatment according toefficacy and tollerability in the treatment of depression in neurologic disorders.

Keywords: depression, neurologic disorders, antidepressants

Received: February 8, 2016; Accepted: February 22, 2018; Prepublished online: April 17, 2018; Published: July 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Racková S. Depression in neurologic disorders, incidence and its treatment. Neurol. praxi. 2018;19(3):213-217. doi: 10.36290/neu.2018.147.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aguiar CC, Almeida AB, Araújo PV, Vasconcelos GS, Chaves EM, do Vale OC, Mac?do DS, de Sousa FC, Viana GS, Vasconcelos SM. Anticonvulsant effects of agomelatine in mice. Epilepsy Behav 2012; 24(3): 324-328. Go to original source... Go to PubMed...
    2. Aguiar CC, Almeida AB, Araújo PV, Vasconcelos GS, Chaves EM, do Vale OC, Mac?do DS, Leal LK, de Barros Viana GS, Vasconcelos SM. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell Mol Neurobiol 2013; 33(6): 825-835. Go to original source... Go to PubMed...
    3. Avila A, Cardona X, Martin-Baranera M, Leon L, Caballol N, Millet P, Bello J. Agomelatine for depression in Parkinson disease: additional effect on sleep and motor dysfunction. J Clin Psychopharmacol 2015; 35(6): 719-723. Go to original source... Go to PubMed...
    4. Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Moja L. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults. Cochrane Database Syst Rev 2015; (5): CD011681. Go to original source...
    5. Bhattacharjee S, Goldstone L, Ip Q, Warholak T. Depression treatment among adults with multiple sclerosis and depression in ambulatory care settings in the United States. Multiple Sclerosis International 2017; 9. Go to original source... Go to PubMed...
    6. Błaszczyk B, Czuczwar SJ. Epilepsy coexisting with depression. Pharmacol Rep 2016; 68(5): 1084-1092. Go to original source... Go to PubMed...
    7. Boeschoten RE, Braamse AMJ, Beekman ATF, Cuijpers P, van Oppen P, Dekker J, Uitdehaag BMJ. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci 2017; 372: 331-341. Go to original source... Go to PubMed...
    8. Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache 2015; 55(1): 21-34. Go to original source... Go to PubMed...
    9. Farina N, Morrell L, Banerjee S. What is the therapeutic value of antidepressants in dementia? A narrative review. Int J Geriatr Psychiatry 2017; 32(1): 32-49. Go to original source... Go to PubMed...
    10. Graham C, Lewis S, Forbes J, Mead G, Hackett ML, Hankey GJ, Gommans J, Nguyen HT, Lundström E, Isaksson E, Näsman P, Rudberg AS, Dennis M. The FOCUS, AFFINITY and EFFECTS trials studying the effect(s) of fluoxetine in patients with a recent stroke: statistical and health economic analysis plan for the trials and for the individual patient data meta-analysis. Trials 2017;18(1):627. Go to original source... Go to PubMed...
    11. Guglielmo R, Martinotti G, Di Giannantonio M, Janiri L. A possible new option for migraine management: agomelatine. Clin Neuropharmacol 2013; 36(2): 65-67. Go to original source... Go to PubMed...
    12. Chi S, Wang C, Jiang T, Zhu XC, Yu JT, Tan L. The prevalence of depression in Alzheimer's disease: a systematic review and meta-analysis. Curr Alzheimer Res 2015; 12(2): 189-198. Go to original source... Go to PubMed...
    13. Jackson JL, Mancuso JM, Nickoloff S, Bernstein R, Kay C. Tricyclic and tetracyclic antidepressants for the prevention of frequent episodic or chronic tension-type headache in adults: a systematic review and meta-analysis. J Gen Intern Med 2017; 32(12): 1351-1358. Go to original source... Go to PubMed...
    14. Kožený J, Höschl C, Tišanská L. Komorbidita migrény a deprese - metaanalytická studie. Cesk Slov Neurol N 2013; 76/109(6): 712-716.
    15. Kraglund KL, Mortensen JK, Grove EL, Johnsen SP, Andersen G. TALOS: a multicenter, randomized, double-blind, placebo-controlled trial to test the effects of citalopram in patients with acute stroke. Int J Stroke 2015; 10(6): 985-987. Go to original source... Go to PubMed...
    16. Liu J, Dong J, Wang L, Su Y, Yan P, Sun S. Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis. PLoS One. 2013; 8(10): e76651. Go to original source... Go to PubMed...
    17. Maguire MJ, Weston J, Singh J, Marson AG. Antidepressants for people with epilepsy and depression. Cochrane Database Syst Rev 2014; 12: CD010682. Go to original source... Go to PubMed...
    18. Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, Hackett ML. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 2012; 11: CD009286. Go to original source... Go to PubMed...
    19. Mirsky MM, Marrie RA, Rae-Grant A. Antidepressant drug treatment in association with multiple sclerosis disease-modifying therapy: using explorys in the MS population. Int J MS Care 2016; 18(6): 305-310. Go to original source... Go to PubMed...
    20. Orgeta V, Tabet N, Nilforooshan R, Howard R. Efficacy of antidepressants for depression in Alzheimer's disease: systematic review and meta-analysis. J Alzheimers Dis 2017; 58(3): 725-733. Go to original source... Go to PubMed...
    21. Pérez LP, González RS, Lázaro EB. Treatment of mood disorders in multiple sclerosis. Curr Treat Options Neurol 2015; 17(1): 323. Go to original source... Go to PubMed...
    22. Plasencia-García BO, Romero-Guillena SL, Quirós-López A, Ruiz-Doblado S. Agomelatine and migraine management: a successfully treated case series. Ther Adv Psychopharmacol 2015; 5(4): 243-245. Go to original source... Go to PubMed...
    23. Qiu BY, Qiao JX, Yong J. Meta-analysis of Selective Serotonin Reuptake Inhibitors (SSRIs) Compared to Tricyclic Antidepressants (TCAs) in the Efficacy and Safety of Anti-depression Therapy in Parkinson's Disease (PD) Patients. Iran J Pharm Res. 2014 Fall; 13(4): 1213-1219.
    24. Raskin S, Durst R. Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments. Med Hypotheses 2010; 75(6): 544-546. Go to original source... Go to PubMed...
    25. Ribot R, Ouyang B, Kanner AM. The impact of antidepressants on seizure frequency and depressive and anxiety disorders of patients with epilepsy: Is it worth investigating? Epilepsy Behav 2017; 70: 5-9. Go to original source... Go to PubMed...
    26. Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W; SAD-PD Study Group. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78(16): 1229-1236. Go to original source... Go to PubMed...
    27. Robinson RG, Jorge RE. Post-stroke depression: A review. Am J Psychiatry 2016; 173(3): 221-231. Go to original source... Go to PubMed...
    28. Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011; (2): CD008191. Go to original source...
    29. Sharma RK, Singh T, Mishra A, Goel RK. Relative safety of different antidepressants for treatment of depression in chronic epileptic animals associated with depression. J Epilepsy Res 2017; 7(1): 25-32. Go to original source... Go to PubMed...
    30. Schippling S, O'Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, Cook S, Filippi M, Hartung HP, Comi G, Jeffery DR, Kappos L,Goodin DS, Arnason B. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol 2016; 263(7): 1418-1426. Go to original source... Go to PubMed...
    31. Schneider F, Althaus A, Backes V, Dodel R. Psychiatric symptoms in Parkinson's disease. Eur Arch Psychiatry Clin Neurosci 2008; 258(suppl 5): 55-59. Go to original source... Go to PubMed...
    32. Siegert RJ, Abernethy DA. Depression in multiple sclerosis: a review. J. Neurol. Neurosurg. Psychiatry 2005; 76: 469-475. Go to original source... Go to PubMed...
    33. Siepmann T, Penzlin AI, Kepplinger J, Illigens BM, Weidner K, Reichmann H, Barlinn K. Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. Brain Behav 2015; 5(10): e00373. Go to original source... Go to PubMed...
    34. Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol 2010; 10: 1-11. Go to original source... Go to PubMed...
    35. Štětkářová I, Horáček J. Epileptogenní potenciál psychofarmak. Cesk Slov Neurol N 2016; 79/112(6): 626-638. Go to original source...
    36. Švestka J. Epileptogenní potenciál psychofarmak. Psychiatr. praxi 2001.
    37. Trivedi MH, Kurian BT. Managing depressive disorders in patients with epilepsy. Psychiatry (Edgmont) 2007; 4(1): 26-34.
    38. Vimala PV, Bhutada PS, Patel FR. Therapeutic potential of agomelatine in epilepsy and epileptic complications. Med Hypotheses 2014; 82(1): 105-110. Go to original source... Go to PubMed...
    39. Zhang Y, Zhao H, Fang Y, Wang S, Zhou H. The association between lesion location, sex and poststroke depression: Meta-analysis. Brain Behav 2017; 7(10): e00788. Go to original source... Go to PubMed...
    40. Wallin MT, Wilken JA, Turner AP, Williams RM, Kane R. Depression and multiple sclerosis: review of a lethal combination. J Rehabil Res Dev 2006; 43(1): 45-62. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.